Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed Hodgkin's lymphoma
• •* Recurrent or refractory disease after prior standard combination chemotherapy
• •Measurable disease, defined as ≥ 1 unidimensionally measurable lesion \> 1 cm by physical exam or imaging studies
• •No history of non-Hodgkin's lymphoma
• •No history of other hematological malignancy
• •PATIENT CHARACTERISTICS:
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Platelet count ≥ 100,000/mm\^3
• •Absolute neutrophil count ≥ 1,000/mm\^3
• •Hepatic
• •Bilirubin ≤ 2 times upper limit of normal (ULN) (unless due to Gilbert's disease or involvement by Hodgkin's lymphoma)
• •AST ≤ 3 times ULN (unless due to involvement by Hodgkin's lymphoma)
• •Renal
• •Creatinine clearance ≥ 30 mL/min
• •Cardiovascular
• •Ejection fraction ≥ 40% by MUGA or echocardiogram (in patients with a history of cardiac disease)
• •Pulmonary
• •Must not require supplemental oxygen therapy
• •Immunologic
• •No known HIV infection
• •No uncontrolled bacterial, viral, or fungal infection
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No other malignancy requiring therapy
• •No peripheral neuropathy ≥ grade 2 within the past 14 days
• •No hypersensitivity to boron
• •No hypersensitivity to mannitol
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •More than 30 days since prior monoclonal antibody therapy for Hodgkin's lymphoma
• •More than 6 months since prior autologous stem cell transplantation
• •No prior allogeneic stem cell transplantation
• •No concurrent sargramostim (GM-CSF)
• •No concurrent pegfilgrastim or filgrastim (G-CSF)
• •No concurrent interleukin-11(oprelvekin)
• •Chemotherapy
• •See Disease Characteristics
• •More than 30 days since prior chemotherapy for Hodgkin's lymphoma
• •No prior treatment with gemcitabine hydrochloride
• •Endocrine therapy
• •More than 30 days since prior corticosteroid therapy for Hodgkin's lymphoma
• •No concurrent corticosteroid therapy
• •Radiotherapy
• •More than 30 days since prior radiotherapy for Hodgkin's lymphoma
• •Other
• •No prior treatment with bortezomib
• •More than 14 days since prior investigational drugs
• •No other concurrent investigational agents